Oncocross is expanding its business from drug discovery to diagnostics and clinical applications,
powered by an AI platform that leverages multi-omics data, creating new possibilities in precision medicine.
Our Business Value Chain
Neo Omics
LC/MS analysis services based on cell, tissue, and liquid specimens
DBB
Assetization of clinical, omics, and pathology data
ONCOfind AI + Early Cancer Detection & Monitoring
Expansion into diagnostics and clinical applications
RAPTOR AI v2.0
AI platform supporting indication exploration and novel modality development
Why Partner With Oncocross
Business in Detail
Neo Omics provides high-quality multi-omics analysis services for cell, tissue, and liquid specimens, including blood and plasma, based on advanced LC/MS analytical equipment and fully automated end-to-end infrastructure.
Leveraging integrated synergy with OncoMaster, we are pursuing the establishment of a Digital Bio-Bank (DBB) that organically connects clinical (RWD), omics, and pathology data.
By converting generated data into analyzable assets, we strengthen the foundation for data-driven collaborative research, customized analysis, and future data business expansion.
ONCOfind AI® is expanding beyond prediction of the primary tumor site into early cancer detection and post-treatment monitoring.
Through multi-omics-based analysis, it precisely interprets cancer-related molecular signals and serves as the final application stage that connects data assets and AI technology to diagnostic and clinical application potential.
Platform Technologies
RAPTOR AI Version 2.0
An AI platform that supports indication discovery, mechanism-of-action interpretation, and advanced multi-omics-based data analysis for candidate compounds
ONCOfind AI®
An expanded application model for predicting the primary site of cancer and for early detection/post-treatment monitoring
Pipeline Highlights
Based on AI-driven discovery and collaborative research capabilities,
we are developing selected key pipelines and partner programs.
News & IR
Notice
Latest News and Updates
Press Releases
Media Coverage and Press Materials
Knowledge Hub
Research and Academic Content Archive
Disclosure Information
Corporate Disclosures and Announcements
Stock Information
Real-time Stock and Investor Information
Let's Build the Next Possibility in Precision Medicine